HOME / Notice / News / EN
NKCL Bio group Inc. (hereinafter referred to as NKCL Bio Group) is a Korean bio company that researches and develops NK immune cell treatment using NK immune cell with its competitive technology. Last year, it had laid the foundation for popularizing NK immune cell treatment by opening the constructi...
Source: [Medical Observer] http://www.monews.co.kr/news/articleView.html?idxno=207654 “Enforcement ordinance for Advanced Regenerative Bio Law will be prepared in February” “We need to move beyond the bio-similar to the original developing phase”, said Kang Soek-Yeon, director of Biopharmaceutica...
Through the main sponsorship of Oscars Viewing Awards, NKCL declared its global marketing to the world. On February 9th, NKCL Bio Group Inc., declared its debut to the global market as the main sponsor of Oscars Viewing Awards, which was held in Hollywood, LA. Shin Donghwa, the Chairman of NKCL Bio G...
NKCL Bio group singing MOU regarding promotion and performing procedure with Suwon Campus Medical Clinic Chairman of NKCL Bio group Shin Dong-Hwa (Left), Director of Campus Medical Clinic Song Yoo-Seok(Right) NKCL Bio Group Inc. (Hereinafter referred to as ‘NKCL Bio Group’) is a bio enterprise that...
NKCL Bio Group Inc. (Hereinafter NKCL Bio Group) received grand award at ‘Promising Brand (Immune Care Platform)’ section in ‘Korea Superb Brand Award 2020’ ceremony, which was hosted by Han-Kyung BUSINESS of Korea Economic Magazine and organized by the Korea Marketing forum on 21th January, 2020...